Category Archives: Non-U.S. Practice

Biotech IP Newsletters

Find below biotech IP newsletters recently provided by Dr. Stefan Danner. SPCs For Combination Products – Opinion Of The Advocate General EPO Ruling On The Patentability Of Medical Treatments By Therapy  

Posted in Non-U.S. Practice | Tagged , , , , | Leave a comment

One step ahead and one step backward for the EU patent

The following is a contribution from Camilla Rendal Nielsen of Zacco Denmark A/S 1.   The EU Competiveness Council have authorised “enhanced cooperation” in the area of unitary patent protection, and. 2.   The EU court now states that the proposed Patents Court … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , , , | Leave a comment

Canadian Ruling Supports “Antibody Exception”

In my recent post on the Centocor v. Abbott decision, I noted that the Fed. Cir. had at least preserved the “antibody exception,” which I define as permitting broad claims to structurally uncharacterized antibodies (monoclonal and polyclonal) if the structure … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , , , , | Leave a comment

A Scheme For Maximizing The Benefits Available Under The Patent Prosecution Highway (PPH)

This post is from Mark Horsburgh of Fisher Adams Kelly in Australia. Summary File in Australia first; Request expedited examination (report issues within 3 months); Address objections and obtain acceptance; File in USA and request entry to PPH (faster and … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , , , | Leave a comment